Zoledronic Acid
Cold Chain RequiredFDA Approved, EMA Approved
Description
Zoledronic acid is a potent bisphosphonate that inhibits osteoclastic bone resorption through binding to bone mineral surfaces. It is used in osteoporosis treatment and has shown efficacy in managing avascular necrosis by preserving bone architecture and preventing collapse. The drug is administered as an annual intravenous infusion.
Indications & Therapeutic Use
osteoporosis, Paget's disease, idiopathic avascular necrosis (off-label), bone metastases
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Zoledronic Acid
| Generic Name | Zoledronic Acid |
| Brands | 1 brand available |
| Active Ingredient | Zoledronic Acid |
| Drug Class | osteoporosis |
| Manufacturer | Novartis |
| Dosage Forms | IV infusion, 5mg/100mL |
| Medical Code | M05BA08 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes